WuXi XDCResults

WuXi XDC H1 2026: Revenue RMB 3.70B, Up 37.0%; Adjusted Net Profit RMB 1.03B, Up 37.4%

H1 revenue RMB 3,701.4M (+37.0% AER / +41.5% CER), gross profit RMB 1,371.3M (+40.6%), adjusted net profit attributable to owners RMB 1,027.3M (+37.4%) at a 27.8% margin; 814 global clients, 328 iCMC programs, backlog ~US$2.0B (+50.4%); Singapore XmAb/XBCM3 achieved GMP release in August and BioDlink integration completed.

On August 24, 2026, WuXi XDC Cayman Inc. (2268.HK), a leading global bioconjugate CRDMO, announced its interim results for the six months ended June 30, 2026. Group revenue increased to RMB 3,701.4 million, representing 37.0% year-over-year growth on an actual exchange rate (AER) basis and 41.5% on a constant exchange rate (CER) basis. The growth was primarily driven by continued expansion of the global ADC and broader XDC market, the company's rising share as a leading ADC CRDMO, and the steady advancement of its projects into later stages.

Margins and profitability improved in tandem: gross profit grew 40.6% to RMB 1,371.3 million, with a gross margin of 37.0% (up 0.9 ppts from 2025 1H); adjusted net profit attributable to owners rose 37.4% to RMB 1,027.3 million, with the adjusted margin holding steady at 27.8% (up 0.1 ppt). The improvement reflected gains in operating and manufacturing efficiency, high capacity utilization on strong demand, successful ramp-up of production lines and a higher share of value-added services, together with disciplined SG&A control.

The customer and project base scaled further: the global customer total reached 814, with 15 of the top-20 global pharma companies now engaged; integrated CMC (iCMC) programs totaled 328 (51 newly signed in H1), including 286 integrated ADC and 42 integrated XDC programs. The commercial and PPQ pipeline comprised 2 commercial projects and 21 PPQ programs (2 newly signed in H1). In H1 the Group explored over 3,100 bioconjugate molecules and has cumulatively explored over 22,000 ADC/XDC molecules. Service backlog grew to ~US$2.0B (+50.4% YoY); including potential milestone fees, total backlog reached ~US$2.2B (+62.2% YoY).

The integrated technology platform kept iterating. The clinically validated WuXiDARx™ conjugation platform has advanced 8 ADC pipelines from preclinical to clinical stages, with WuXiDAR4™ enabling 10+ iCMC programs (8 in clinical development). Within WuXi Payload-Linker™, the exatecan-based WuXiTecan-2™ has been applied via licensing to 3 iCMC-stage programs (with Earendil Labs and a European biotech) and pushed the first dual-payload ADC (MMAE + WuXiTecan-2™) from PCC into iCMC development; X-LinC™, a stable conjugation connector, improves in-vivo ADC stability by reducing payload-linker deconjugation.

Capacity and operations expanded: headcount rose to 3,628, with WuXi XDC's standalone workforce over 3,100 and more than 50% holding a master's degree or above; the Group has completed 200+ global client GMP audits, including 27 EU QP audits. The acquisition of BioDlink closed in March 2026, adding capacity and clients; in August the Singapore site's XmAb/XBCM3 achieved GMP release, marking the Group's first manufacturing site outside mainland China, with XDP4 scheduled for GMP release by end-August. Looking ahead, Wuxi will add XDP5/XDP6 drug-product lines and Jiangyin's XPLM2 will secure vertical integration of the critical payload-linker supply chain. The company was named 'Best CDMO' for three consecutive years (2023–2025) at the World ADC Awards and 'Best CRO' in 2025.

This article is compiled from public reporting. Original source: 药明合联官方公众号(2026 年中期业绩) · For industry reference only; not investment advice.